Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Gain Therapeutics management to meet virtually with Oppenheimer » 04:55
06/15/21
06/15
04:55
06/15/21
04:55
GANX

Gain Therapeutics

$9.79 /

-0.34 (-3.36%)

Virtual Meetings to be…

Virtual Meetings to be held on June 14-15 hosted by Oppenheimer.

ShowHide Related Items >><<
GANX Gain Therapeutics
$9.79 /

-0.34 (-3.36%)

GANX Gain Therapeutics
$9.79 /

-0.34 (-3.36%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$9.79 /

-0.34 (-3.36%)

Monday
Conference/Events
Gain Therapeutics management to meet virtually with Oppenheimer » 04:55
06/14/21
06/14
04:55
06/14/21
04:55
GANX

Gain Therapeutics

$10.13 /

-0.02 (-0.20%)

Virtual Meetings to be…

Virtual Meetings to be held on June 14-15 hosted by Oppenheimer.

ShowHide Related Items >><<
GANX Gain Therapeutics
$10.13 /

-0.02 (-0.20%)

GANX Gain Therapeutics
$10.13 /

-0.02 (-0.20%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$10.13 /

-0.02 (-0.20%)

Over a week ago
Conference/Events
Gain Therapeutics management to meet virtually with Oppenheimer » 13:50
06/10/21
06/10
13:50
06/10/21
13:50
GANX

Gain Therapeutics

$10.46 /

+0.31 (+3.05%)

Virtual Meetings to be…

Virtual Meetings to be held on June 14-15 hosted by Oppenheimer.

ShowHide Related Items >><<
GANX Gain Therapeutics
$10.46 /

+0.31 (+3.05%)

GANX Gain Therapeutics
$10.46 /

+0.31 (+3.05%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$10.46 /

+0.31 (+3.05%)

Hot Stocks
Gain Therapeutics announces issuance of two new PCT patents » 07:36
06/10/21
06/10
07:36
06/10/21
07:36
GANX

Gain Therapeutics

$10.15 /

-0.39 (-3.70%)

Gain Therapeutics…

Gain Therapeutics announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfolded beta-glucocerebrosidase and galactosylceramidase respectively, addressing central nervous system and demyelinating disorders such as Parkinson's Disease, Lewy body dementia and Alzheimer's. "This is a pivotal milestone for Gain Therapeutics as these two patents highlight the association between the approach to treating rare diseases, such as Gaucher Disease and Krabbe Disease, and the approach to treating more widely prevalent and growing disease states like Parkinson's Disease and Multiple Sclerosis," said Eric Richman, Chief Executive Officer of Gain. "The two issued patents reflect our focus and commitment to developing first in class therapies for these CNS and lysosomal storage diseases, and we are excited to strengthen our intellectual property and advance our potential to treat patients with these devastating diseases."

ShowHide Related Items >><<
GANX Gain Therapeutics
$10.15 /

-0.39 (-3.70%)

GANX Gain Therapeutics
$10.15 /

-0.39 (-3.70%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$10.15 /

-0.39 (-3.70%)

Conference/Events
Gain Therapeutics management to meet virtually with Oppenheimer » 04:55
06/10/21
06/10
04:55
06/10/21
04:55
GANX

Gain Therapeutics

$10.15 /

-0.39 (-3.70%)

Virtual Meeting to be…

Virtual Meeting to be held on June 10 hosted by Oppenheimer.

ShowHide Related Items >><<
GANX Gain Therapeutics
$10.15 /

-0.39 (-3.70%)

GANX Gain Therapeutics
$10.15 /

-0.39 (-3.70%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$10.15 /

-0.39 (-3.70%)

Conference/Events
Gain Therapeutics management to meet virtually with Oppenheimer » 11:24
06/09/21
06/09
11:24
06/09/21
11:24
GANX

Gain Therapeutics

$10.50 /

-0.04 (-0.38%)

Virtual Meeting to be…

Virtual Meeting to be held on June 10 hosted by Oppenheimer.

ShowHide Related Items >><<
GANX Gain Therapeutics
$10.50 /

-0.04 (-0.38%)

GANX Gain Therapeutics
$10.50 /

-0.04 (-0.38%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$10.50 /

-0.04 (-0.38%)

Over a month ago
Conference/Events
Gain Therapeutics management to meet virtually with BTIG » 04:55
05/18/21
05/18
04:55
05/18/21
04:55
GANX

Gain Therapeutics

$9.61 /

-0.09 (-0.93%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17-18 hosted by BTIG.

ShowHide Related Items >><<
GANX Gain Therapeutics
$9.61 /

-0.09 (-0.93%)

GANX Gain Therapeutics
$9.61 /

-0.09 (-0.93%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$9.61 /

-0.09 (-0.93%)

Conference/Events
Gain Therapeutics management to meet virtually with BTIG » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
GANX

Gain Therapeutics

$9.70 /

+0.5 (+5.43%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17-18 hosted by BTIG.

ShowHide Related Items >><<
GANX Gain Therapeutics
$9.70 /

+0.5 (+5.43%)

GANX Gain Therapeutics
$9.70 /

+0.5 (+5.43%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$9.70 /

+0.5 (+5.43%)

Conference/Events
Gain Therapeutics management to meet virtually with BTIG » 16:45
05/13/21
05/13
16:45
05/13/21
16:45
GANX

Gain Therapeutics

$9.20 /

-0.545 (-5.59%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17-18 hosted by BTIG.

ShowHide Related Items >><<
GANX Gain Therapeutics
$9.20 /

-0.545 (-5.59%)

GANX Gain Therapeutics
$9.20 /

-0.545 (-5.59%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$9.20 /

-0.545 (-5.59%)

Hot Stocks
Gain Therapeutics present in Vitro, in Vivo data from its GBA1 Parkinson program » 07:33
05/03/21
05/03
07:33
05/03/21
07:33
GANX

Gain Therapeutics

$11.75 /

-0.5 (-4.08%)

Gain Therapeutics…

Gain Therapeutics announced new pre-clinical data from its GBA1 Parkinson's disease program. The findings were highlighted in a presentation at the XXVI International Association of Parkinsonism and Related Disorders World Congress, a research conference dedicated to Parkinson's disease and other disorders affecting muscle tone and motor control, being held virtually May 1-4. Preclinical Development of Brain-Penetrant Structurally Targeted Allosteric Regulators, or STARs, for the Treatment of GBA1 Parkinson's Disease and Related alpha-Synucleopathies. The presented results highlight data from preclinical cell cultures and rodent models, including rotenone models of Parkinson's disease. STARs bound misfolded forms of GCase trapped in the endoplasmic reticulum, or ER, and enhanced the processing from the ER to the lysosome. This improved lysosomal GCase activity restored normal lysosomal and autophagic activity and ultimately decreased alpha-synuclein levels. Two lead STAR candidates were identified using Gain's proprietary SEE-Tx drug discovery platform. Both STAR compounds stabilized GCase and enhanced its enzymatic activity in human fibroblasts isolated from patients with GBA1-related Gaucher disease, which has a similar genetic profile to Parkinson's disease. Both STAR compounds were neuroprotective and lowered alpha-synuclein pathology in primary rat dopaminergic neurons. When delivered orally, GT-02329 successfully penetrated the blood brain barrier and enhanced GCase activity and protein levels in the striatum of wild-type mice. GT-02287 reduced alpha-synuclein accumulation in both cell culture and rat models of Parkinson's disease. GT-02287 improved locomotor activity in rats treated with rotenone, a model of Parkinson's disease that reproduces certain features of the human disease.

ShowHide Related Items >><<
GANX Gain Therapeutics
$11.75 /

-0.5 (-4.08%)

GANX Gain Therapeutics
$11.75 /

-0.5 (-4.08%)

04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 Oppenheimer
Gain Therapeutics initiated with an Outperform at Oppenheimer
04/12/21 BTIG
Gain Therapeutics initiated with a Buy at BTIG
  • 18
    Mar
GANX Gain Therapeutics
$11.75 /

-0.5 (-4.08%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.